Our proprietary Cav1.2 Cell Line
Host cell: CHO-K1
Platforms: Fluorescence, QPatch
Tested reference inhibitors: Nifedipine, Verapamil, Isradipine
Tested reference activators: FPL64176
Cav1.2 ion channels are expressed in heart, smooth muscle, and neurons, and therefore are therapeutic targets in cardiac arrhythmia and hypertension. Due to their key role in shaping the cardiac action potential, they are part of the CiPA-compliant panel of the human ion channel to be tested for cardiac safety.
Key features of our Cav1.2 cell line:
- Stable expression of all three subunits of the native Cav1.2 channel (α1c/β2/α2δ)
- High success rates and reliable performance in automated patch clamp assays
- Run-down free recordings
- Inducible system: easy to maintain in cell culture, adjustable expression level
Other Ion Channel Cell Lines
Together with our partner, Steinbeis-Innovationszentrum Zellkulturtechnik, we develop ion channel cell lines based on the proprietary IGAMI technology.
The IGAMI inducible expression device combines two inducible expression systems in one cell. The expression of two different genes of interests can be controlled by different specific antibodies. After induction, the respective transactivator induces the expression of a gene of interests as well as its own expression.
This technique has been shown to be an excellent choice for the development of cell lines for difficult targets in ion channel screening.
Our cell lines are optimized for automated patch clamp platforms, like Sophions Qpatch.
List of IGAMI ion channel cell lines:
- CaV1.2 cell line
- nACHR alpha7 cell line
Please contact us if you are interested in customized ion channel cell line development.